The difference between giritinib and Iressa

Gilteritinib and Iressa are two completely different drugs. Iressa is the brand name of gefitinib (Gefitinib) sold in China, while the brand name of Gefitinib is segatan. Giritinib and gefitinib are both tyrosine kinase inhibitors, but they have different targets and indications and are used to treat different types of cancer.

Giritinib is a tyrosine kinaseFLT3 inhibitor, mainly used to treat certain hematological malignancies, especially relapsed or refractory cases of acute myeloid leukemia (AML) patients with FLT3 gene mutations. Giritinib inhibits the growth and spread of leukemia cells by blocking the FLT3 signaling pathway.

Gefitinib is an epidermal growth factor receptor inhibitor, mainly used to treat patients with certain EGFR (epidermal growth factor receptor) gene mutations in non-small cell lung cancer (NSCLC), especially for continued treatment after failure of platinum or docetaxel chemotherapy. Gefitinib inhibits the growth and spread of tumor cells by inhibiting the activity of EGFR and blocking abnormal signaling.

The original drug of giritinib has been launched in China, but it has not yet been included in the medical insurance. The price of each box of 40mg*42 tablets may be more than 20,000 yuan, and the price of the Hong Kong version of the original drug is about 90,000 yuan per box. The price of the European version of the original drug, 40mg*84 tablets, per box listed overseas is around RMB 210,000 (the price may fluctuate due to exchange rates), which is very expensive. Generic drugs of giritinib are currently produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 40mg*84 tablets per box produced by a Laos pharmaceutical factory is more than 4,000 yuan (the price may fluctuate due to the exchange rate).